TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04775485: A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Sponsor: Day One Biopharmaceuticals, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 141 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT04775485 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04775485 Rescue Dossier →